CN112313236A - 噻吩并嘧啶酮化合物 - Google Patents

噻吩并嘧啶酮化合物 Download PDF

Info

Publication number
CN112313236A
CN112313236A CN201980036091.5A CN201980036091A CN112313236A CN 112313236 A CN112313236 A CN 112313236A CN 201980036091 A CN201980036091 A CN 201980036091A CN 112313236 A CN112313236 A CN 112313236A
Authority
CN
China
Prior art keywords
unsubstituted
substituted
compound
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980036091.5A
Other languages
English (en)
Chinese (zh)
Inventor
凯尔·W·H·程
阿帕瑞吉塔·荷思可特·克瑞西亚
保罗·E·艾德曼
方黎
伊梅尔达·朗姆
法兰克·默库里奥
罗伯特·沙利文
爱德华多·托雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayorsrix Co
Original Assignee
Bayorsrix Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayorsrix Co filed Critical Bayorsrix Co
Publication of CN112313236A publication Critical patent/CN112313236A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201980036091.5A 2018-03-30 2019-03-28 噻吩并嘧啶酮化合物 Pending CN112313236A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650922P 2018-03-30 2018-03-30
US62/650,922 2018-03-30
PCT/US2019/024612 WO2019191451A1 (en) 2018-03-30 2019-03-28 Thienopyrimidinone compounds

Publications (1)

Publication Number Publication Date
CN112313236A true CN112313236A (zh) 2021-02-02

Family

ID=66102328

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980036091.5A Pending CN112313236A (zh) 2018-03-30 2019-03-28 噻吩并嘧啶酮化合物

Country Status (8)

Country Link
US (1) US10584133B2 (https=)
EP (1) EP3774815A1 (https=)
JP (1) JP2021519786A (https=)
CN (1) CN112313236A (https=)
AU (1) AU2019243186A1 (https=)
CA (1) CA3094988A1 (https=)
TW (1) TW202003524A (https=)
WO (1) WO2019191451A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023001028A1 (zh) * 2021-07-19 2023-01-26 南京明德新药研发有限公司 杂芳-3-哌啶二酮类化合物及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021105335A1 (en) * 2019-11-27 2021-06-03 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
WO2021207530A1 (en) * 2020-04-08 2021-10-14 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202237580A (zh) 2020-12-14 2022-10-01 美商拜歐斯瑞克斯公司 Pde4降解劑、醫藥組合物及治療應用
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド イソインドリノン化合物
WO2022255890A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120220631A1 (en) * 2005-09-27 2012-08-30 Tianjin Hemay Bio-Tech Co., Ltd. USE OF 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AS TUMOR NECROSIS FACTOR INHIBITOR
US20140314753A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc. Methods for treating cancer using tor kinase inhibitor combination therapy
WO2017120446A1 (en) * 2016-01-08 2017-07-13 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
CN110099907A (zh) * 2016-12-21 2019-08-06 拜欧赛里克斯公司 靶向蛋白质的噻吩并吡咯衍生物、组合物、方法及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334596A (en) 1993-05-11 1994-08-02 Merck & Co., Inc. Fibrinogen receptor antagonists
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
DE60326436D1 (en) 2002-03-13 2009-04-16 Janssen Pharmaceutica Nv Aminoderivate als histone-deacetylase-inhibitoren
KR101153335B1 (ko) 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
WO2005047293A1 (en) 2003-11-07 2005-05-26 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
EP2616442B8 (en) 2010-09-14 2018-10-17 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
AU2012229300B2 (en) * 2011-03-11 2017-04-20 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
KR101446680B1 (ko) 2013-02-08 2014-10-07 한국과학기술연구원 ｍＧｌｕＲ1 길항제로 작용하는 사이에노피리미디논 유도체
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
RU2018117503A (ru) 2015-10-27 2019-11-28 Мерк Шарп И Доум Корп. ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ
US11395820B2 (en) * 2016-03-16 2022-07-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
US10406165B2 (en) * 2017-03-14 2019-09-10 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120220631A1 (en) * 2005-09-27 2012-08-30 Tianjin Hemay Bio-Tech Co., Ltd. USE OF 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AS TUMOR NECROSIS FACTOR INHIBITOR
US20140314753A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc. Methods for treating cancer using tor kinase inhibitor combination therapy
WO2017120446A1 (en) * 2016-01-08 2017-07-13 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
CN110099907A (zh) * 2016-12-21 2019-08-06 拜欧赛里克斯公司 靶向蛋白质的噻吩并吡咯衍生物、组合物、方法及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARY E. MATYSKIELA，等: "A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase", 《NATURE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023001028A1 (zh) * 2021-07-19 2023-01-26 南京明德新药研发有限公司 杂芳-3-哌啶二酮类化合物及其应用

Also Published As

Publication number Publication date
TW202003524A (zh) 2020-01-16
AU2019243186A1 (en) 2020-10-15
US20190322682A1 (en) 2019-10-24
US10584133B2 (en) 2020-03-10
WO2019191451A1 (en) 2019-10-03
EP3774815A1 (en) 2021-02-17
JP2021519786A (ja) 2021-08-12
CA3094988A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
CN112313236A (zh) 噻吩并嘧啶酮化合物
US11345714B2 (en) Compounds targeting proteins, compositions, methods, and uses thereof
US10562917B2 (en) Chimeric compounds targeting proteins, compositions, methods, and uses thereof
CN109071552B (zh) 细胞周期蛋白依赖性激酶4/6(cdk4/6)通过cdk4/6抑制剂与e3连接酶配体的缀合的降解及使用方法
KR20220023343A (ko) 단백질 표적 화합물, 이의 약학 조성물 및 이들의 치료적 적용
CN113423701A (zh) 取代的异吲哚啉酮
TW202019936A (zh) 雙功能化合物
KR20180005174A (ko) 단백질을 표적하는 화합물, 조성물, 방법, 및 그의 용도
EP1879894A1 (en) Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
KR101707761B1 (ko) 브루톤 티로신 키나아제 억제제로서의 티아졸 유도체
TW200922572A (en) Heterocyclic antiviral compounds
JP2024534757A (ja) Ｐｄ－ｌ１相互作用の免疫調節剤としての化合物
EA052590B1 (ru) Молекулы protac белка malt1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210202

WD01 Invention patent application deemed withdrawn after publication